Text says 'Lafora Disease Therapeutic Overview presented by Dr. Kit Donohue'

Lafora Disease Therapeutic Overview

/by

We invite you to watch a video and read a page about the Lafora Disease Therapeutic Overview as of August 2023.

Are you wondering if there are future therapy options for Lafora Disease? Also, what treatments are in progress?

At last week’s event, Ask the Experts: A Q&A for Lafora Families, Chelsea’s Hope Science Director, Dr. Kit Donohue, shared an overview of treatment options in the pipeline. We are happy to share a short recording from the Q&A, as well as a PDF page with information from the presentation slideshow.

If you registered for the event, we’ve already sent you the full recording and handout. Make sure to check your email!

Watch Lafora Disease Therapeutic Overview on YouTube

We hope the Q&A was informative and that participants could get their questions answered. Our team will work on creating handouts on Lafora Disease stages and on the importance of testing siblings of Lafora Disease patients. Please let us know if there are other resources we can provide to help you navigate living with Lafora.

Finally, Chelsea’s Hope is grateful for any volunteer who can translate materials from English to other languages. We encourage you to fill out the volunteer interest form if you can assist us.

Access the Lafora Disease Therapeutic Overview video captions in English HERE.

Access the transcript in Italian HERE.

Please email Dr. Donohue if you have any follow-up questions from the Q&A.

Download Therapeutic Overview PDF
You might also like
Dear Noventia Pharma Team, We are families affected by Lafora disease who are holding on to hope through your work. Your dedication to developing a treatment for Lafora means everything to us. We were excited when you shared the news of the ION283 license purchase and your intentions to create a clinical trial last year, but we are anxiously awaiting more details. We know that any future progress with ION283 will come from your company, so we kindly request a public update on what is next for the drug’s development after the safety study at UTSW. As you know, the current ION283 safety study includes only 10 children. While we are grateful this study is happening, many more families were heartbroken to learn our children could not participate. These families are now left waiting, watching their children’s condition progress, and praying for the next opportunity. We are counting on Noventia to help make that opportunity possible. For many of us, your work is the only hope we have left. Our children do not have time to wait. Lafora disease is aggressive and unforgiving—we are pleading for a chance to save our children’s lives. We desperately urge Noventia to share your plans and move forward quickly with a clinical trial or expanded access program so more children can receive this potentially life-saving treatment. You have our full support in this mission, and we are willing to assist however we can.READ ARTICLE: The democratization of science could speed up healthcare research
Text says 'Ask the experts: a q&a for Lafora families' over a white and gray hexagonal background.Ask the Experts: A Q&A Session for Lafora Families
ION238 Safety Study Update February 2025Safety Study Update – February 2025
18 June 2025 wednesday Register online to attend the Zoom meeting. ION283: what's next? Q&A Submit your questions beforehand.Announcing June 18th ION283 Q&A: What’s Next?
Dear Noventia Pharma Team, We are families affected by Lafora disease who are holding on to hope through your work. Your dedication to developing a treatment for Lafora means everything to us. We were excited when you shared the news of the ION283 license purchase and your intentions to create a clinical trial last year, but we are anxiously awaiting more details. We know that any future progress with ION283 will come from your company, so we kindly request a public update on what is next for the drug’s development after the safety study at UTSW. As you know, the current ION283 safety study includes only 10 children. While we are grateful this study is happening, many more families were heartbroken to learn our children could not participate. These families are now left waiting, watching their children’s condition progress, and praying for the next opportunity. We are counting on Noventia to help make that opportunity possible. For many of us, your work is the only hope we have left. Our children do not have time to wait. Lafora disease is aggressive and unforgiving—we are pleading for a chance to save our children’s lives. We desperately urge Noventia to share your plans and move forward quickly with a clinical trial or expanded access program so more children can receive this potentially life-saving treatment. You have our full support in this mission, and we are willing to assist however we can.Open Letter to Noventia
Childhood Dementia WebinarsTitle text on the left says 'upcoming webinars.' Below is a bullet point list of text that says 'Childhood Dementia Introduction Tue. 5th September 10:30 - 11:30 pm EST Accessing Emerging Treatments for Childhood Dementia Thu. 7th September 6 - 6:45 pm EST We Don't Fit Report Tue. 10th October 9:30 - 10:30 pm EST.' On the right text says 'hosted by: Childhood Dementia Intiative. Colorful ovals are in the top right corner and the Chelsea's Hope Lafora Children Research Fund logo is in the bottom right corner.The background is bright yellow. On the left is a child with blue face paint. To the right is another child, who has red, white, and black face paint on, Between the children, the text reads, 'FACE it To make childhood dementia impossible to ignore'.FACE it Campaign